Abstract
Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.
Original language | English (US) |
---|---|
Pages (from-to) | 221-260 |
Number of pages | 40 |
Journal | American journal of clinical pathology |
Volume | 147 |
Issue number | 3 |
DOIs | |
State | Published - Mar 1 2017 |
Keywords
- Molecular diagnostics
- gastrointestinal
- genetics
- histology
- oncology
ASJC Scopus subject areas
- Pathology and Forensic Medicine